Literature DB >> 26304554

Animal models for the study of HCV.

Koen Vercauteren1, Ype P de Jong2, Philip Meuleman3.   

Abstract

The development and evaluation of effective therapies and vaccines for the hepatitis C virus (HCV) and the study of its interactions with the mammalian host have been hindered for a long time by the absence of suitable small animal models. Immune compromised mouse models that recapitulate the complete HCV life cycle have been useful to investigate many aspects of the HCV life cycle including antiviral interventions. However, HCV has a high propensity to establish persistence and associated histopathological manifestations such as steatosis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Better understanding of these processes requires the development of a permissive and fully immunocompetent small animal model. In this review we summarize the in vivo models that are available for the study of HCV.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26304554      PMCID: PMC4549803          DOI: 10.1016/j.coviro.2015.04.009

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  117 in total

1.  Toxicology. 'Humanized' mouse detects deadly drug side effects.

Authors:  Jon Cohen
Journal:  Science       Date:  2014-04-18       Impact factor: 47.728

2.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Authors:  Marc Lütgehetmann; Lida V Mancke; Tassilo Volz; Martina Helbig; Lena Allweiss; Till Bornscheuer; Joerg M Pollok; Ansgar W Lohse; J Petersen; Stephan Urban; Maura Dandri
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

3.  Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures.

Authors:  Alexander Ploss; Salman R Khetani; Christopher T Jones; Andrew J Syder; Kartik Trehan; Valeriya A Gaysinskaya; Kathy Mu; Kimberly Ritola; Charles M Rice; Sangeeta N Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

4.  Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

Authors:  Katja Giersch; Martina Helbig; Tassilo Volz; Lena Allweiss; Lida V Mancke; Ansgar W Lohse; Susanne Polywka; Jörg M Pollok; Jörg Petersen; John Taylor; Maura Dandri; Marc Lütgehetmann
Journal:  J Hepatol       Date:  2013-11-23       Impact factor: 25.083

5.  Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins.

Authors:  Shingo Takikawa; Ronald E Engle; Kristina N Faulk; Suzanne U Emerson; Robert H Purcell; Jens Bukh
Journal:  J Gen Virol       Date:  2009-11-11       Impact factor: 3.891

6.  Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication.

Authors:  Niki Vassilaki; Peter Friebe; Philipe Meuleman; Stephanie Kallis; Artur Kaul; Glaucia Paranhos-Baccalà; Geert Leroux-Roels; Penelope Mavromara; Ralf Bartenschlager
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

7.  Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.

Authors:  Frank Narjes; Benedetta Crescenzi; Marco Ferrara; Jörg Habermann; Stefania Colarusso; Maria del Rosario Rico Ferreira; Ian Stansfield; Angela Claire Mackay; Immacolata Conte; Caterina Ercolani; Simone Zaramella; Maria-Cecilia Palumbi; Philip Meuleman; Geert Leroux-Roels; Claudio Giuliano; Fabrizio Fiore; Stefania Di Marco; Paola Baiocco; Uwe Koch; Giovanni Migliaccio; Sergio Altamura; Ralph Laufer; Raffaele De Francesco; Michael Rowley
Journal:  J Med Chem       Date:  2010-12-08       Impact factor: 7.446

8.  Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice.

Authors:  Jizheng Chen; Yang Zhao; Chao Zhang; Hairong Chen; Jin Feng; Xiumei Chi; Yu Pan; Jun Du; Min Guo; Huang Cao; Honghe Chen; Zilong Wang; Rongjuan Pei; Qian Wang; Lei Pan; Junqi Niu; Xinwen Chen; Hong Tang
Journal:  Cell Res       Date:  2014-08-26       Impact factor: 25.617

9.  Extensive double humanization of both liver and hematopoiesis in FRGN mice.

Authors:  Elizabeth M Wilson; J Bial; Branden Tarlow; G Bial; B Jensen; D L Greiner; M A Brehm; M Grompe
Journal:  Stem Cell Res       Date:  2014-09-06       Impact factor: 2.020

10.  Evidence for novel hepaciviruses in rodents.

Authors:  Jan Felix Drexler; Victor Max Corman; Marcel Alexander Müller; Alexander N Lukashev; Anatoly Gmyl; Bruno Coutard; Alexander Adam; Daniel Ritz; Lonneke M Leijten; Debby van Riel; Rene Kallies; Stefan M Klose; Florian Gloza-Rausch; Tabea Binger; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Mathieu Bourgarel; Daniel Rupp; Bernd Hoffmann; Mathias Schlegel; Beate M Kümmerer; Detlev H Krüger; Jonas Schmidt-Chanasit; Alvaro Aguilar Setién; Veronika M Cottontail; Thiravat Hemachudha; Supaporn Wacharapluesadee; Klaus Osterrieder; Ralf Bartenschlager; Sonja Matthee; Martin Beer; Thijs Kuiken; Chantal Reusken; Eric M Leroy; Rainer G Ulrich; Christian Drosten
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823

View more
  9 in total

1.  Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.

Authors:  Thibaut Vausselin; Karin Séron; Muriel Lavie; Ahmed Atef Mesalam; Matthieu Lemasson; Sandrine Belouzard; Lucie Fénéant; Adeline Danneels; Yves Rouillé; Laurence Cocquerel; Lander Foquet; Arielle R Rosenberg; Czeslaw Wychowski; Philip Meuleman; Patricia Melnyk; Jean Dubuisson
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

2.  Hepatitis C virus's next top models?

Authors:  David Paul; Ralf Bartenschlager
Journal:  Nat Microbiol       Date:  2016-01-11       Impact factor: 17.745

3.  Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection.

Authors:  Benjamin Y Winer; Tiffany Huang; Benjamin E Low; Cindy Avery; Mihai-Alexandru Pais; Gabriela Hrebikova; Evelyn Siu; Luis Chiriboga; Michael V Wiles; Alexander Ploss
Journal:  Virology       Date:  2016-12-19       Impact factor: 3.616

4.  A mouse model for hepatitis C virus infection: are we there yet?

Authors:  Cordelia Manickam; R Keith Reeves
Journal:  Ann Infect       Date:  2017-11-30

5.  Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.

Authors:  Tanvi Khera; Daniel Todt; Koen Vercauteren; C Patrick McClure; Lieven Verhoye; Ali Farhoudi; Sabin Bhuju; Robert Geffers; Thomas F Baumert; Eike Steinmann; Philip Meuleman; Thomas Pietschmann; Richard J P Brown
Journal:  Antiviral Res       Date:  2017-01-03       Impact factor: 10.103

6.  Opposite Effects of Two Human ATG10 Isoforms on Replication of a HCV Sub-genomic Replicon Are Mediated via Regulating Autophagy Flux in Zebrafish.

Authors:  Yu-Chen Li; Miao-Qing Zhang; Jing-Pu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-04       Impact factor: 5.293

7.  Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo.

Authors:  Yue Feng; Yue-Mei Feng; Caixia Lu; Yuanyuan Han; Li Liu; Xiaomei Sun; Jiejie Dai; Xueshan Xia
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

Review 8.  Maternal natural killer cells at the intersection between reproduction and mucosal immunity.

Authors:  Evgeniya V Shmeleva; Francesco Colucci
Journal:  Mucosal Immunol       Date:  2021-04-26       Impact factor: 7.313

9.  Characterization of RNA Sensing Pathways in Hepatoma Cell Lines and Primary Human Hepatocytes.

Authors:  Wiebke Nicolay; Rebecca Moeller; Sina Kahl; Florian W R Vondran; Thomas Pietschmann; Stefan Kunz; Gisa Gerold
Journal:  Cells       Date:  2021-11-04       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.